Patents by Inventor Genevieve WEIR

Genevieve WEIR has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220143165
    Abstract: The present application relates to vaccine compositions comprising an amphipathic compound, a neoantigen and a hydrophobic carrier. Further described are methods and use of the vaccine composition for inducing an antibody immune response and/or a cell-mediated immune response to the neoantigen, as well as methods and uses of the vaccine compositions in the treatment of cancer.
    Type: Application
    Filed: January 21, 2022
    Publication date: May 12, 2022
    Applicant: IMMUNOVACCINE TECHNOLOGIES INC.
    Inventors: Marianne STANFORD, Genevieve WEIR, Frederic ORS, Leeladhar SAMMATUR
  • Publication number: 20220125903
    Abstract: The present application relates generally to methods for treating tumors, and in particular to methods for improving the efficacy of a survivin therapeutic in the treatment of tumors by improving survivin specific T cell infiltration in tumor.
    Type: Application
    Filed: November 18, 2019
    Publication date: April 28, 2022
    Applicant: IMMUNOVACCINE TECHNOLOGIES INC.
    Inventors: Marianne STANFORD, Stephan FISET, Lisa MACDONALD, Genevieve WEIR, Rajkannan RAJAGOPALAN
  • Patent number: 11260116
    Abstract: The present application relates to vaccine compositions comprising an amphipathic compound, a neoantigen and a hydrophobic carrier. Further described are methods and use of the vaccine composition for inducing an antibody immune response and/or a cell-mediated immune response to the neoantigen, as well as methods and uses of the vaccine compositions in the treatment of cancer.
    Type: Grant
    Filed: May 3, 2017
    Date of Patent: March 1, 2022
    Assignee: IMMUNOVACCINE TECHNOLOGIES INC.
    Inventors: Marianne Stanford, Genevieve Weir, Frederic Ors, Leeladhar Sammatur
  • Publication number: 20210147544
    Abstract: The present disclosure relates to the targeted delivery of defined active agents and/or immunomodulatory agents to lymph nodes or lipoid cells in a lymphatic tissue. More particularly, the invention provides methods for targeted delivery of a defined active agent or immunomodulatory agent to lymph nodes or lymphoid cells in a lymphatic tissue, comprising administering to a subject in need thereof a composition comprising the active agent or immunomodulatory agent, one or more lipid-based structures, and a hydrophobic carrier.
    Type: Application
    Filed: March 18, 2019
    Publication date: May 20, 2021
    Applicant: IMMUNOVACCINE TECHNOLOGIES INC.
    Inventors: Rajkannan RAJAGOPALAN, Leeladhar SAMMATUR, Marianne STANFORD, Heather TORREY, Genevieve WEIR
  • Publication number: 20200353062
    Abstract: The present disclosure relates to methods for preparing a dried preparation comprising lipids and therapeutic agents whereby the therapeutic agents are incorporated both before and after sizing of lipid vesicle particles to a mean particle size of ?120 nm and a polydispersity index (PDI) of ?0.1. The present application also provides stable, water-free pharmaceutical compositions comprising one or more lipid-based structures having a single layer lipid assembly, at least two therapeutic agents, and a hydrophobic carrier, as well as methods of treatment, uses and kits relating thereto, such as for example for inducing an antibody and/or CTL immune response.
    Type: Application
    Filed: November 9, 2017
    Publication date: November 12, 2020
    Applicant: IMMUNOVACCINE TECHNOLOGIES INC.
    Inventors: Leeladhar SAMMATUR, Rajkannan RAJAGOPALAN, Arthvan SHARMA, Valarmathy KALIAPERUMAL, Genevieve WEIR, Marianne STANFORD, Andrea PENWELL
  • Publication number: 20200230057
    Abstract: The present disclosure relates to methods for preparing a dried preparation comprising lipids and a therapeutic agent by using lipid vesicle particles having a mean particle size of ?120 nm and a polydispersity index (PDI) of ?0.1. The present application also provides stable, water-free pharmaceutical compositions comprising one or more lipid-based structures having a single layer lipid assembly, at least one therapeutic agent, and a hydrophobic carrier, as well as methods of treatment, uses and kits relating thereto, such as for example for inducing an antibody and/or CTL immune response.
    Type: Application
    Filed: November 9, 2017
    Publication date: July 23, 2020
    Applicant: IMMUNOVACCINE TECHNOLOGIES INC.
    Inventors: Leeladhar SAMMATUR, Rajkannan RAJAGOPALAN, Arthvan SHARMA, Valarmathy KALIAPERUMAL, Genevieve WEIR, Marianne STANFORD, Andrea PENWELL
  • Publication number: 20190151428
    Abstract: The present application relates to vaccine compositions comprising an amphipathic compound, a neoantigen and a hydrophobic carrier. Further described are methods and use of the vaccine composition for inducing an antibody immune response and/or a cell-mediated immune response to the neoantigen, as well as methods and uses of the vaccine compositions in the treatment of cancer.
    Type: Application
    Filed: May 3, 2017
    Publication date: May 23, 2019
    Applicant: IMMUNOVACCINE TECHNOLOGIES INC.
    Inventors: Marianne STANFORD, Genevieve WEIR, Frederic ORS, Leeladhar SAMMATUR